During the past decade, Especialidades Medicas LYS conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Especialidades Medicas LYS" are "Alzheimer Disease" (4 trials), "Alzheimer's Disease" (2 trials), "Agitation and Aggression in Alzheimer's Disease" (1 trials) and "Dementia-related Psychosis" (1 trials). Many other conditions were trialed in "Especialidades Medicas LYS" in a lesser frequency.

Most popular intervention types in "Especialidades Medicas LYS" are "Drug" (8 trials). Other intervention types were less common.

The name of intervention was led by "Gantenerumab" (4 trials), "Placebo" (4 trials), "Pimavanserin" (1 trials), "Pimavanserin 20 mg" (1 trials) and "Pimavanserin 34 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Especialidades Medicas LYS" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Especialidades Medicas LYS". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Especialidades Medicas LYS, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Especialidades Medicas LYS, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".